A0A024R0H7 | SWISS-MODEL Repository

A0A024R0H7 (A0A024R0H7_HUMAN) Homo sapiens (Human)

Methylosome protein WDR77 UniProtKB InterPro Interactive Modelling

342 aa; Sequence (Fasta) ; 1 identical sequence: Homo sapiens: Q9BQA1

Available Structures

53 Experimental Structures

Description	PDB ID	Oligo-state	Range	Ligands
Crystal structure of PRMT5:MEP50 with EPZ015866 and sinefungin	5c9z SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	16-328	1×SFG; 1×4Z2; 1×GOL;
Assess
Crystal structure of PRMT5:MEP50 with Compound 15 and sinefungin	5emm SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	16-328	4×SFG; 4×5QL; 8×GOL;
Assess
Crystal structure of PRMT5:MEP50 with Compound 9 and sinefungin	5emk SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	16-328	4×SFG; 4×5QH; 8×GOL;
Assess
PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (compound (M)-31)	7s1r SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-329	1×MTA; 1×85E;
Assess
PRMT5/MEP50 with compound 30 bound	7ser SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-329	1×97L; 1×MTA;
Assess
PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 34	7kic SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	18-328	6×EDO; 1×WFS;
Assess
PRMT5-MEP50 Complexed with SAM	7l1g SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	18-328	15×EDO; 2×CL; 1×SAM;
Assess
PRMT5/MEP50 with compound 29 bound	7ses SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-329	1×97X; 1×MTA;
Assess
PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 72	7kid SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	18-328	4×EDO; 1×WFV;
Assess
PRMT5:MEP50 Complexed with Cyclonucleoside Compound 1	7u30 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	18-328	8×EDO; 1×LB3;
Assess
PRMT5/MEP50 crystal structure with MTA and MRTX-1719 bound	7s1s SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-329	1×MTA; 1×85K;
Assess
PRMT5/MEP50 crystal structure with MTA and an achiral, class 1, non-atropisomeric inhibitor bound	7uoh SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-329	1×NXF; 1×MTA;
Assess
CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJB44355437	7bo7 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-329	1×U6K; 1×EPE; 3×EDO; 1×PEG;
Assess
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound	7zvu SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-328	2×MTA; 2×UNL; 4×GOL;
Assess
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound	7zuy SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-328	1×MTA; 1×UNL; 2×GOL;
Assess
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound	7zv2 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-328	1×MTA; 1×UNL; 2×GOL;
Assess
Human PRMT5:MEP50 structure with Fragment (Example 18) and MTA Bound	7zup SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-328	1×MTA; 1×JYX; 2×GOL;
Assess
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound	7zuu SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-328	1×MTA; 1×UNL; 2×GOL;
Assess
Crystal structure of PRMT5:MEP50 with EPZ015666 and sinefungin	4x60 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-328	1×SFG; 1×3XV; 3×GOL;
Assess
Crystal structure of PRMT5:MEP50 with Compound 10 and SAM	5eml SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-328	4×SAM; 4×5QK; 8×GOL;
Assess
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound	7zvl SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-328	1×MTA; 1×UNL; 2×GOL; 1×CL;
Assess
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound	7zuq SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-328	1×MTA; 2×GOL; 1×UNL;
Assess
PRMT5:MEP50 complexed with inhibitor PF-06939999	7mx7 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	20-329	4×ZR1;
Assess
PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 4	7kib SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-328	1×WFM; 10×EDO; 3×CL; 2×PEG;
Assess
PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 8	6uxy SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-328	1×QKY; 1×EDO; 1×GOL;
Assess
HUMAN PRMT5:MEP50 COMPLEX WITH MTA and Fragment 5 Bound	7uy1 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	20-329	1×PJ0; 1×MTA; 1×SO4; 2×EDO; 3×PEG; 2×CL;
Assess
PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 1a	6uxx SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	19-328	1×QL1;
Assess
PRMT5:MEP50 complexed with inhibitor PF-06855800	7mxa SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	20-329	4×ZR4;
Assess
Crystal Structure of the human PRMT5:MEP50 Complex	4gqb SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; P62805; Q9BQA1;	21-329	4×0XU;
Assess
CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ44064146	6rll SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	21-329	1×K8H;
Assess
CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ45031882	6rlq SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	21-329	1×K8N;
Assess
Structure of PRMT5:MEP50 in complex with LLY-283, a potent and selective inhibitor of PRMT5, with a…	6ckc SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	21-329	4×F5J;
Assess
PRMT5 bound to the PBM peptide from pICln	6v0o SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; P54105; Q9BQA1;	21-329	4×SFG; 4×ACE;
Assess
Crystal structure of PRMT5:MEP50 with EPZ015666 and SAH	4x63 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	20-328	1×SAH; 1×3XV;
Assess
Cryo-EM structures and computational analysis for enhanced potency in MTA-synergic inhibition of hu…	8cyi SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	21-329	1×P2R; 1×MTA;
Assess
Crystal Structure of PRMT5:MEP50 in complex with MTA and H4 peptide	5fa5 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; P62805; Q9BQA1;	21-328	4×MTA;
Assess
Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase (PRMT5) Inhibitors	6k1s SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	21-328	1×CUX; 1×DMS; 7×EDO;
Assess
Cryo-EM structure of the apo form of human PRMT5:MEP50 complex at a resolution of 3.4 angstrom	6ugh SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	23-329
Assess
PRMT5 bound to PBM peptide from Riok1	6v0n SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1; Q9BRS2;	23-328	4×SFG;
Assess
PRMT5:MEP50 complexed with adenosine	7mxc SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	24-329	4×ADN;
Assess
PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (Compound 9)	7s1q SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	23-328	1×MTA; 1×84W;
Assess
Structure of the methylosome-Lsm10/11 complex	8g1u SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; P83369; Q61189; Q9BQA1;	23-328	4×ADN;
Assess
CryoEM structure of PRMT5 bound to covalent PBM-site inhibitor BRD-6988	7m05 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	23-328	4×YJG;
Assess
Human PRMT5:MEP50 structure with Fragment 3 and MTA Bound	8ctb SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	24-328	1×PWX; 1×MTA;
Assess
Human PRMT5:MEP50 structure with Fragment 4 and MTA Bound	7uyf SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	25-329	1×PUI; 1×MTA; 3×PEG; 3×CL;
Assess
Crystal structure of PRMT5:MEP50 with EPZ015666 and SAM	4x61 SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	24-328	1×SAM; 1×3XV; 1×GOL;
Assess
PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06939999	7mxn SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	26-329	1×ZR1;
Assess
PRMT5/MEP50 crystal structure with MTA and phthalazinone fragment bound	7s0u SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	27-329	1×CL; 1×NA; 1×EDO; 1×81X; 1×MTA;
Assess
Crystal structure of PRMT5:MEP50 with Compound 8 and sinefungin	5emj SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	26-328	4×SFG; 4×5QJ; 16×GOL;
Assess
PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06855800	7mxg SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	27-329	4×ZR4;
Assess
Human PRMT5:MEP50 structure with Fragment 1 and MTA Bound	8csg SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	27-329	1×PWL; 1×MTA; 3×PEG; 2×EDO;
Assess
PRMT5 complex bound to covalent PBM inhibitor BRD6711	6v0p SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	27-328	4×QN4; 8×CL; 4×SFG; 8×GOL;
Assess
PRMT5/MEP50 crystal structure with sinefungin bound	7s1p SMTL PDBe PDBe-KB PDBj PDBsum RCSB	Heteromer O14744; Q9BQA1;	27-328	1×SFG;
Assess

1 SWISS-MODEL model

Template	Oligo-state	QMEANDisCo	Range	Ligands	Trg-Tpl Seq id (%)
4gqb.1.B	monomer	0.90	21-329		100.00
Assess

Model ID	Oligo-state	Avg pLDDT	Range	Trg-Mdl Seq Id (%)

Model ID	Oligo-state	Avg Confidence	Range	Trg-Mdl Seq id (%)

A0A024R0H7 (A0A024R0H7_HUMAN) Homo sapiens (Human)

Methylosome protein WDR77 UniProtKBInterProInteractive Modelling

Available Structures

53 Experimental Structures

1 SWISS-MODEL model

Alignments

Background

Resolution

Methylosome protein WDR77 UniProtKB InterPro Interactive Modelling